PROIN ER™ (phenylpropanolamine hydrochloride extended-release tablets)

For the control of canine urinary incontinence due to urethral sphincter hypotonus.

Urethral sphincter hypotonus causes canine urinary incontinence as a result of weakened muscles of the urethral sphincter.

NADA# 141-517

PROIN^® works by increasing urethral sphincter muscle tone to help prevent urinary leakage.

FDA Approved Phenylpropanolamine Hydrochloride Medication For The Treatment Of Urinary Incontinence Due To Urethral Sphincter Hypotonus.

What are the common clinical signs of urinary incontinence in dogs?

• Dripping or leaking urine
• Excessive licking of the genital area
• Red and irritated skin around the genital area
• Needing to go more frequently than normal
• Wetting the bed or sleeping area
• Urinating inappropriately in the house

Fortunately, while frustrating at first, canine urinary incontinence may be controlled with PROIN ER™, a safe and effective FDA-approved once-a-day tablet that works by increasing urethral sphincter tone to help prevent urinary accidents.

Why PROIN ER^™?

• Convenient – Given with food, a single dose per day simplifies treatment
• Innovative – Patented release technology provides controlled release that ensures steady absorption
• Easy to Administer – Chewable, liver-flavored tablets improve compliance
• Easy to Prescribe – Four dosing strengths based on body weight to provide simplicity
• FDA Approved – FDA approved for control of urinary incontinence due to urethral sphincter hypotonus in dogs

*See package insert for important safety information and full prescribing instructions, located here

Category:

• Urinary Health

• Canine

Supplied:

Contact your veterinarian immediately if your dog ingests more than the prescribed dose.

Important safety information:

For oral use in dogs only. Not for human use. Keep out of reach of children. If accidentally ingested by humans, contact a physician immediately.

The most commonly reported side effects were vomiting, loss of appetite, diarrhea, excessive salivation, agitation, tiredness, vocalization, confusion, increased water consumption, weight loss, weakness, fever, panting, and reversible changes in skin color (flushing or bright pink). Abnormal gait, seizures or tremors, as well as liver enzyme elevations, kidney failure, blood in urine and urine retention have been reported. In some cases death, including euthanasia has been reported. Sudden death was sometimes preceded by vocalization or collapse.

Instances of dogs chewing through closed vials of PROIN® and eating the vial contents have been reported, in some cases resulting in overdose. Keep the product in a secured storage area out of the reach of pets in order to prevent accidental ingestion or overdose, as dogs may willingly consume more than the recommended dosage of PROIN® chewable tablets or PROIN ER™ tablets. Contact your veterinarian immediately if the dog ingests more tablets than prescribed or if other pets ingest PROIN® chewable tablets or PROIN ER™ tablets.

PROIN® and PROIN ER™ may cause elevated blood pressure and should be used with caution in dogs with pre-existing heart disease, high blood pressure, liver disease, kidney insufficiency, diabetes, glaucoma, and other conditions associated with high blood pressure. Dogs may transition from PROIN® chewable tablets to PROIN ER™ without a break in administration. However, do not alternate PROIN ER™ with PROIN® chewable tablets because the effectiveness and safety of interchangeable use have not been evaluated.

The safe use of PROIN® and PROIN ER™ in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated. Contact your veterinarian if you notice restlessness or irritability, loss of appetite, the incontinence persists or worsens, or any other unusual signs. See prescribing information for complete details regarding adverse events, warning and precautions.